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Abstract In the present study we used K562 cells to demon-
strate that insulin receptor substrate 1 (IRS-1) is expressed and
constitutively phosphorylated in BCR-ABL+ cells. We observed
association between BCR-ABL/IRS-1, IRS-1/phosphoinositide
3P-kinase (PI3-kinase), and IRS-1/Grb2 in the K562 cell line.
Our ¢ndings demonstrate that imatinib treatment resulted in
marked attenuation of BCR-ABL/IRS-1 association and of
IRS-1-stimulated PI3-kinase activity in K562 cells. We con-
cluded that the IRS-1 protein is involved in the signalling path-
way of the BCR-ABL tyrosine kinase.
1 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The signalling network controlled by BCR-ABL is complex
and highly redundant [1]. The sum of these protein interac-
tions translates into the altered phenotype of CML cells,
which consists of constitutively active mitogenic signalling,
defective adherence to stromal cells and extracellular matrix,
and reduced response to apoptosis-inducing stimuli [2]. The
tyrosine kinase activity of BCR-ABL is speci¢cally inhibited
by imatinib mesylate, formerly STI571 [3^6].
The insulin receptor substrate (IRS) signalling system me-
diates cell growth and metabolism during insulin/insulin-like
growth factor 1 (IGF-1) and interleukin-4 (IL-4) stimulation
[7]. The best characterized member of the family, IRS-1, con-
tains multiple tyrosine phosphorylation sites, which during
insulin stimulation are phosphorylated and act as docking
sites for the SH2 domains of the p85 regulatory subunit of
phosphoinositide 3P-kinase (PI3-kinase) [8,9], the adapter pro-
tein Grb-2 that links it to the Ras signalling cascade [10],
SHP-2 phosphatase, and the Nck protein [11,12]. IRS-1 is
detected in most cells and tissues, including lymphoid progen-
itor cells, B cells, carcinoma cells, ¢broblasts, adipocytes, liv-
er, skeletal muscle and brain.
To further extend our understanding of the mechanisms by
which BCR-ABL transforms cells, we have attempted to iden-
tify more proteins that interact with BCR-ABL and which
might direct BCR-ABL to various signal transduction path-
ways. In the present study we sought to determine whether
BCR-ABL induces IRS-1 phosphorylation and whether this
association requires BCR-ABL tyrosine kinase activity. We
also thought of determining whether the function of the
IRS-1 system is required for activation of PI3-kinase in
BCR-ABL signalling and whether the IRS-1 phosphorylation
leads to association with Grb-2. Therefore we evaluated the
e¡ects of imatinib on BCR-ABL/Grb2 association and on the
levels of total extracellular signal-regulated kinase (ERK) and
phospho-ERK expression in K562 cells treated or not with
imatinib.
2. Materials and methods
2.1. Cell culture and imatinib treatment
The human leukemia cell lines K562 and HL60 were obtained from
ATCC, Philadelphia, PA, USA. Cells were cultured in RPMI contain-
ing 10% fetal calf serum and glutamine with addition of penicillin/
streptomycin and amphotericin B, they were maintained at 37‡C, 5%
CO2. For experiments, cells were seeded at a density of 3U105 cells/ml
and cultured for 7 days. K562 cells were incubated or not with 1 WM
imatinib for 6 h. Imatinib was kindly provided by Dr. Elizabeth
Buchdunger, Novartis Pharmaceuticals, Basel, Switzerland, and pre-
pared as a 50 mM stock solution in sterile water. Samples containing
1U107 cells were pelletted and resuspended in lysis bu¡er (1% Triton
X-100, 100 mM Tris (pH 7.4), 100 mM sodium pyrophosphate, 100
mM sodium £uoride, 10 mM EDTA, 10 mM sodium vanadate, 2 mM
phenylmethylsulfonyl £uoride, and 0.1 mg/ml aprotinin) and incuba-
ted for 30 min at 4‡C. Insoluble material was removed by centrifuga-
tion for 45 min at 12 000 rpm in a 70.Ti rotor (Beckman) at 4‡C.
Protein determination was performed by the Bradford dye method
[13] using the Bio-Rad reagent and bovine serum albumin as the stan-
dard.
2.2. Western blotting analysis
Equal amounts of protein were used for total extracts or for im-
munoprecipitation with speci¢c antibodies followed by SDS^PAGE
and Western blot analysis with the indicated antibodies and
[125I]protein A as described [8,14], or ECL1 Western Blotting Anal-
ysis System (Amersham Pharmacia Biotech UK Limited). Quantita-
tive analysis of the blots was performed using Scion Image Software.
Monoclonal antibodies against phosphotyrosine (SC-508), Abl (SC-
23), phospho-ERK (SC-7383) and polyclonal antibody against IRS-1
(SC-559), Grb2 (SC-255) and ERK1 (SC-93) were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-PI3-kinase antiserum
(06-195) was from UBI (Lake Placid, NY, USA). To con¢rm the
IRS-1 presence, we also performed immunoblottings with a rabbit
polyclonal antibody against IRS-1 that was kindly provided by Dr.
Morris, F. White and X.J. Sun (Joslin Diabetes Center, Boston, MA,
USA). To exclude unspeci¢c interactions between the investigated
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proteins and protein A-Sepharose, control precipitations without the
speci¢c antibodies were performed, followed by immunoblotting with
anti-phosphotyrosine, anti-IRS-1, anti-Abl and anti-PI3-kinase anti-
bodies and no band was detected. The results indicated that the im-
munoprecipitations performed in the experiments described herein do
not allow the detection of unspeci¢c interactions.
2.3. PI3-kinase assay
Aliquots of supernatants containing equal amounts of protein were
incubated overnight at 4‡C using antibody against IRS-1, and the
immunocomplexes were precipitated with a 50% solution of protein
A-Sepharose 6MB. In vitro PI3-kinase assays were performed as de-
scribed [8]. The 32P-labeled 3-P-phosphatidylinositol was quantitated
using Scion Image Software.
2.4. Statistical analysis
Experiments were performed by analyzing K562 cells treated and
untreated with imatinib. For comparisons, Student’s unpaired t-test
was used. The level of signi¢cance was set at P6 0.05.
3. Results
3.1. BCR-ABL oncoprotein binds to IRS-1 and is constitutively
phosphorylated
K562 cells were either left untreated or treated with imati-
nib for 6 h, and cell lysates were immunoprecipitated with an
anti-Abl antibody and then immunoblotted with anti-phos-
photyrosine. A 210 kDa protein band corresponding to tyro-
sine-phosphorylated BCR-ABL was detected. The level of
phosphorylation of this band decreased after imatinib treat-
ment. In the same anti-phosphotyrosine blots, in addition to
the 210 kDa band, another band of 185 kDa was also de-
Fig. 1. IRS-1 is a substrate of BCR-ABL protein. IRS-1 is phosphorylated by BCR-ABL. A: K562 cells were exposed (+) or not (3) to 1 WM
imatinib for 6 h. Lysates from K562 cells containing equal amounts of protein were immunoprecipitated (IP) with anti-Abl antibodies and im-
munoblotted (IB) with anti-phosphotyrosine antibodies (P-Tyr) as described in Section 2. The nitrocellulose membrane was stripped and re-
probed with anti-IRS-1 antibodies (B), and with anti-Abl antibodies (C) (n=12). Imatinib inhibits tyrosine phosphorylation of IRS-1. D: K562
cells treated with 1 WM imatinib at the time indicated were immunoprecipitated with anti-IRS-1 and blotted with anti-phosphotyrosine antibody
(P-Tyr). The same membrane was stripped and reblotted with anti-Abl and anti-IRS-1 antibodies (n=4). E: K562 cells treated for 6 h with
di¡erent concentrations of imatinib, as indicated, were immunoprecipitated with anti-IRS-1 and blotted with anti-phosphotyrosine antibody
(P-Tyr). The same membrane was stripped and reblotted with anti-Abl and anti-IRS-1 antibodies (n=4). The Western blots were developed
with the ECL Western Blotting Analysis System.
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tected, and there was a very marked decline in this band after
treatment (Fig. 1A). By reprobing this membrane with anti-
IRS-1 antibody, we demonstrated that the 185 kDa band
corresponds to IRS-1, and the level of this band was not
modi¢ed by imatinib treatment, showing that the association
IRS-1/BCR-ABL occurs independently of IRS-1 tyrosine
phosphorylation (Fig. 1B). This result was con¢rmed by im-
munoblotting with another anti-IRS-1 antibody (kindly pro-
vided by Dr. Morris, F. White) (data not shown). As pre-
dicted, there were no changes in BCR-ABL protein levels
(Fig. 1C).
We con¢rmed this result by Western blotting analysis of
tyrosine-phosphorylated proteins in anti-IRS-1 immunopreci-
pitates before and after imatinib treatment. In order to esti-
mate the rate of imatinib-induced inhibition of IRS-1 phos-
phorylation in K562 cells, we performed time course and
dose^response experiments. The time course experiments
were performed in K562 cells treated with 1 WM of imatinib
and collecting samples at di¡erent time points. As shown in
Fig. 1D (upper panel), IRS-1 phosphorylation is strongly in-
hibited after 3 h treatment with 1 WM of imatinib, with max-
imal inhibition occurring at 6 h and sustained for 12 h. The
levels of BCR-ABL associated with IRS-1 were the same after
imatinib treatment (Fig. 1D). There were no changes in IRS-1
protein levels (Fig. 1D, bottom panel). Subsequently, the
dose^response curve was performed using K562 cells treated
for 6 h with di¡erent concentrations of imatinib. As shown in
Fig. 1E (upper panel), there was a dose-dependent decrease in
IRS-1 phosphorylation after imatinib treatment. The IRS-1
phosphorylation almost disappeared with 1 WM imatinib
treatment for 6 h. When the nitrocellulose membrane was
stripped and immunoblotted with anti-Abl antibody, the
BCR-ABL association with IRS-1 protein occurred indepen-
dently of the imatinib treatment (Fig. 1E). Reprobing this
nitrocellulose membrane with anti-IRS-1 antibody, there
were no changes in IRS-1 protein levels (Fig. 1E, bottom
panel).
Fig. 2. The level of phosphorylation of IRS-1 in BCR/ABL3 cells is
not inhibited by imatinib. The HL60 cell line was treated (+) or not
(3) with 1 WM imatinib for 6 h. Autoradiograms of SDS^PAGE of
IRS-1 immunoprecipitates (IP) were immunoblotted (IB) with anti-
phosphotyrosine antibodies (P-Tyr). Blots were stripped and re-
probed with anti-IRS-1 antibodies. The results of a representative
study are shown. The bar graphs represent the meanVS.E.M. of
the scanning densitometry of six experiments. The Western blots
were developed with [125I]protein A.
Fig. 3. IRS-1 associates and activates PI3-kinase in K562 cell line. A: K562 cells were exposed (+) or not (3) to 1 WM imatinib for 6 h. Auto-
radiograms of SDS^PAGE of IRS-1 immunoprecipitates (IP) were immunoblotted (IB) with anti-PI3-kinase antibodies. The nitrocellulose trans-
fer was stripped and reblotted with antibodies to IRS-1. The results of a representative study are shown. The bar graphs represent the meanV
S.E.M. of the scanning densitometry of six experiments. The Western blots were developed with [125I]protein A. B: Lysates from K562 cells ex-
posed (+) or not (3) to 1 WM imatinib for 6 h were immunoprecipitated with anti-IRS-1 antibodies. PI3-kinase assays were performed as de-
scribed. Fluorographs show the silica TLC plates of IRS-1-associated PI3-kinase activity. PIP3 indicates the migration position of phosphatidyl-
inositol 3-phosphate. Bar graphs depict the relative incorporation of 32P into PI3-P (meanVS.E.M.) from six separate experiments.
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3.2. IRS-1 phosphorylation is una¡ected by imatinib in
BCR/ABL3 cells
HL60 cells were treated or not with 1 WM imatinib for 6 h.
Cell lysates were immunoprecipitated with anti-IRS-1, fol-
lowed by immunoblotting with anti-phosphotyrosine antibod-
ies. As expected, the levels of IRS-1 protein and IRS-1 tyro-
sine phosphorylation in HL60 cells remained unchanged with
imatinib treatment (Fig. 2). These results demonstrated that
IRS-1 tyrosine phosphorylation was not directly modulated
by imatinib treatment in HL60 cells.
3.3. IRS-1 associates and activates PI3-kinase in K562 cell line
In samples from K562 cells previously immunoprecipitated
with anti-IRS-1 antibody and immunoblotted with antibody
directed against the 85 kDa subunit of PI3-kinase, a band
with the expected molecular weight of the regulatory subunit
of PI3-kinase (85 kDa) was present. The amount of PI3-ki-
nase associated with IRS-1 was reduced to 30V 6% of the
control values (P6 0.05) in K562 cells treated with imatinib
(Fig. 3A), thus suggesting that IRS-1 associates with PI3-ki-
nase in K562 cells and this association depends on the level of
IRS-1 phosphorylation.
To determine if there is PI3-kinase activity in IRS-1 immu-
noprecipitates, K562 cells were prepared and immunoprecipi-
tated with anti-IRS-1 antibodies. A basal PI3-kinase activity
was present in anti-IRS-1 immunoprecipitates in control cells.
After the treatment with imatinib, there was a dramatic de-
crease in PI3-kinase activity (Fig. 3B). Thus, compared with
control cells, the level of PI3-kinase activity in anti-IRS-1
immunoprecipitates was reduced to 26V 10% (P6 0.05) in
K562 cells treated with imatinib. These data suggest that in
IRS-1 immunoprecipitates there is PI3-kinase activity, which
is inhibited by imatinib.
3.4. Grb2, an adapter protein, interacts with IRS-1 in
K562 cells
Cells were treated or not with imatinib and cell lysates were
immunoprecipitated with anti-Grb2 antibody and then immu-
noblotted with anti-phosphotyrosine (Fig. 4A). A 210 kDa
protein, corresponding to tyrosine-phosphorylated BCR-
ABL, was present, as expected. A 185 kDa protein, corre-
sponding to tyrosine-phosphorylated IRS-1, was clearly de-
tectable in anti-Grb-2 immunoprecipitates in control cells.
The levels of BCR-ABL phosphorylation and IRS-1 phos-
Fig. 4. Grb2, an adapter protein, interacts with IRS-1 in K562 cells. K562 cells were exposed (+) or not (3) to 1 WM imatinib for 6 h.
A: Autoradiograms of SDS^PAGE of Grb-2 immunoprecipitates (IP) were immunoblotted (IB) with anti-phosphotyrosine antibodies (P-Tyr).
The Western blot was developed with [125I]protein A. Blots were stripped and reprobed with anti-IRS-1 antibodies (B) and with anti-Abl anti-
bodies (C), and developed with the ECL Western Blotting Analysis System. The results of a representative study are shown. The bar graphs
represent the meanVS.E.M. of the scanning densitometry of eight experiments.
Fig. 5. Imatinib inhibits MAPK phosphorylation/activation in a
time- and dose-dependent manner. A: K562 cells treated with 1 WM
imatinib for the times indicated were lysed and the proteins were
separated by SDS^PAGE on 12% gels and immunoblotted (IB) with
antibodies directed against phospho-ERK1/2. Blots were stripped
and reprobed with anti-total ERK1/2. B: K562 cells treated for 6 h
with di¡erent concentrations of imatinib, as indicated, were lysed
and the proteins were separated by SDS^PAGE on 12% gels and
blotted with antibodies directed against phospho-ERK1/2. Blots
were stripped and reprobed with anti-total ERK1/2. The results of a
representative study are shown (n=4). The Western blots were de-
veloped with the ECL Western Blotting Analysis System.
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phorylation associated with Grb2 were signi¢cantly reduced in
cells treated with imatinib (Fig. 4A). To assess the e¡ect of
imatinib on direct binding of Grb2 to IRS-1, this nitrocellu-
lose membrane was stripped and immunoblotted with anti-
IRS-1 and we observed a 50% decrease in the association
between Grb2/IRS-1 after imatinib treatment (P6 0.05)
(Fig. 4B). By reprobing this membrane with anti-Abl antibod-
ies we con¢rmed that imatinib inhibits the Grb2/BCR-ABL
association (Fig. 4C).
3.5. Imatinib inhibits MAPK phosphorylation/activation
To characterize the e¡ects of imatinib on mitogen-activated
protein kinase (MAPK) activation, expression of phospho-
ERK and total ERK was determined by Western blot analysis
of the total extracts of K562 cells incubated or not with im-
atinib at di¡erent times and doses. The time course experi-
ments were performed in K562 cells treated with 1 WM of
imatinib and collecting samples at di¡erent time points. As
shown in Fig. 5A, ERK1/2 phosphorylation was inhibited
after 6 h of 1 WM imatinib and this inhibition was sustained
for 12 h. The level of ERK1/2 was the same (Fig. 5A, bottom
panel). Subsequently, the dose^response curve was performed
with K562 cells treated for 6 h with di¡erent concentrations of
imatinib. As shown in Fig. 5B, the level of ERK1/2 phosphor-
ylation had almost disappeared after 6 h of 2 WM imatinib
treatment. The total ERK1/2 expression remained una¡ected
with imatinib treatment (Fig. 5B, bottom panel).
4. Discussion
In the present study we demonstrated the involvement of
IRS-1 protein in BCR-ABL signal transduction. We discov-
ered that the IRS-1 protein was phosphorylated in K562 cells
previously immunoprecipitated with anti-Abl antibodies. Us-
ing a BCR-ABL tyrosine kinase inhibitor we discovered that
there was a strong decrease in IRS-1 phosphorylation level,
but independently of the IRS-1 tyrosine phosphorylation lev-
el, this protein interacted with BCR-ABL. These results, taken
together, suggest that IRS-1 is constitutively phosphorylated
and associated with BCR-ABL in K562 cells, and that IRS-1
phosphorylation is inhibited by imatinib. IRS proteins have
been previously shown to be essential for the mitogenic e¡ects
of insulin/IGF-1 and IL-4 in myeloid hematopoietic cells
[7,15], suggesting that IRS-1 regulates cellular pathways crit-
ical for cell metabolism and growth. Even though most of our
knowledge regarding the molecular functions of IRS proteins
has been derived from studies in the insulin signalling system,
our data are the ¢rst evidence that this protein participates in
BCR-ABL signalling pathway.
To clarify the role that IRS-1 protein plays in the BCR-
ABLþ cells, it is necessary to characterize the pathways of
IRS-1 in response to the tyrosine kinase activity of the
BCR-ABL oncoprotein. The role of PI3-kinase in transducing
tyrosine kinase signals is well established [16,17], but the acti-
vation of PI3-kinase by tyrosine kinases may involve di¡erent
mechanisms. Distinct domains from di¡erent proteins mediate
the association of BCR-ABL/PI3-kinase and the activation of
PI3-kinase [18]. IRS-1 contains about nine YMXM motifs,
which bind to PI3-kinase [19]. Using anti-PI3-kinase antibod-
ies in samples previously immunoprecipitated with anti-IRS-1
antibodies, we then demonstrated the association of IRS-1/
PI3-kinase in K562 cells. We also demonstrated the IRS-1-
associated PI3-kinase activity in this cell line. We observed a
signi¢cant decrease in the association between IRS-1 and PI3-
kinase and also in the IRS-1-associated PI3-kinase activity
upon imatinib treatment, which suggests that the mechanism
of activation of PI3-kinase by BCR/ABL involves binding to
IRS-1 phosphorylated protein, and depends on the BCR-ABL
tyrosine kinase activity.
In spite of the fact that imatinib can also inhibit c-kit and
platelet-derived growth factor (PDGF) tyrosine kinase activity
[20], evidence supports our hypothesis that the tyrosine phos-
phorylation of IRS-1 is mediated by BCR-ABL in K562 cell
line. PDGF induces IRS-1 phosphorylation on serine/threo-
nine residues, but not on tyrosine residues [21,22]. On the
other hand, c-kit associates directly with PI3-kinase and this
association depends on tyrosine 719 of the c-kit receptor
[23,24]. As a point mutation in the c-kit receptor abolishes
the PI3-kinase activation, it is unlikely that IRS-1 participates
in the c-kit signalling pathway towards PI3-kinase activation.
So, it is reasonable to speculate that the tyrosine phosphory-
lation of IRS-1, like the IRS-1-associated PI3-kinase activity,
is mediated by BCR-ABL in K562 cells. Furthermore, we
have excluded unspeci¢c inhibition of IRS-1 phosphorylation
by imatinib, since its phosphorylation was not inhibited in
HL-60 human myeloid leukemia cells that do not express
the BCR-ABL kinase activity (BCR-ABL3 cells).
Several links between BCR-ABL and Ras have been de-
¢ned. Autophosphorylation of tyrosine 177 in BCR-ABL pro-
vides a docking site for the adapter molecule Grb-2 [25,26].
Two other adapter molecules, Shc and Crkl, are substrates of
BCR-ABL [27,28] and can also activate Ras. In this study we
demonstrated that BCR-ABL might also recruit the IRS-1
protein, and once phosphorylated, IRS-1 recruits the Grb2
docking protein. The association between Grb2 and BCR-
ABL has been well studied, and this association requires
Y177 phosphorylation, a known autophosphorylation site
on BCR-ABL (PMID: 7553858) [25,29]. Our results show
that the association between Grb2 and BCR-ABL was inhib-
ited by imatinib treatment. These data reinforce that BCR/
ABL may induce the formation of multimeric complexes of
signalling proteins, and in the case of Grb2 activation, IRS-1
participates in this multimeric complex, but is probably not
essential for Grb2 activation in the BCR-ABL pathway. We
also veri¢ed, in K562 cells, the e¡ect of imatinib on the down-
stream proteins involved in the MAPK pathway. As previ-
ously described, imatinib is able to inhibit the MAPK path-
way [20,30,31], and it seems to occur in a time- and dose-
dependent manner.
In conclusion, we identi¢ed that IRS-1 is a new adapter
protein in the BCR-ABL signalling pathway. IRS-1 phosphor-
ylation depends on BCR-ABL tyrosine kinase activity, and is
inhibited by imatinib. The IRS-1 protein, when phosphorylat-
ed by BCR-ABL, can activate the PI3-kinase pathway. Our
results also demonstrated that IRS-1 can bind to Grb2 in
K562 cells. In addition, the results suggest that IRS-1 is in-
volved in the signalling pathway of the BCR-ABL tyrosine
kinase and, by binding to PI3-kinase and Grb2, establishes
a new link between BCR-ABL, Akt and p21ras.
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